[
    [
        {
            "time": "2023-10-01",
            "original_text": "汇添富基金新基谋求中长期稳健增值 刘江一只同类产品长期业绩显疲软 盈利能力下降",
            "features": {
                "keywords": [
                    "汇添富基金",
                    "中长期稳健增值",
                    "刘江",
                    "长期业绩疲软",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "汇添富基金新基谋求中长期稳健增值 刘江一只同类产品长期业绩显疲软 盈利能力下降",
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-02",
            "original_text": "294家医药公司分红582亿！恒瑞攒钱研发，迈瑞慷慨，云南白药分近50亿，Biotech几乎不分！",
            "features": {
                "keywords": [
                    "医药公司",
                    "分红",
                    "恒瑞",
                    "迈瑞",
                    "云南白药",
                    "Biotech"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "294家医药公司分红582亿！恒瑞攒钱研发，迈瑞慷慨，云南白药分近50亿，Biotech几乎不分！",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-03",
            "original_text": "【基金交易日报】招商基金、东方基金旗下债基净值暴涨9%，建信基金新产品延长募集期 净值异常波动",
            "features": {
                "keywords": [
                    "招商基金",
                    "东方基金",
                    "债基",
                    "净值暴涨",
                    "建信基金",
                    "延长募集期",
                    "净值异常波动"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【基金交易日报】招商基金、东方基金旗下债基净值暴涨9%，建信基金新产品延长募集期 净值异常波动",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-04",
            "original_text": "迈瑞医疗：股东Magnifice（HK）累计质押股数为5556万股",
            "features": {
                "keywords": [
                    "迈瑞医疗",
                    "股东",
                    "Magnifice（HK）",
                    "质押",
                    "5556万股"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "迈瑞医疗：股东Magnifice（HK）累计质押股数为5556万股",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "迈瑞医疗(300760.SZ)控股股东Magnifice (HK)质押606万股",
            "features": {
                "keywords": [
                    "迈瑞医疗",
                    "控股股东",
                    "Magnifice (HK)",
                    "质押",
                    "606万股"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "迈瑞医疗(300760.SZ)控股股东Magnifice (HK)质押606万股",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-06",
            "original_text": "医药生物行业2021年中期投资策略报告：拥抱新兴产业方向 把握价值低估标的",
            "features": {
                "keywords": [
                    "医药生物",
                    "投资策略",
                    "新兴产业",
                    "价值低估"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药生物行业2021年中期投资策略报告：拥抱新兴产业方向 把握价值低估标的",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 10,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2023-10-07",
            "original_text": "超千家机构调研这家公司，多只机构调研股涨幅翻倍",
            "features": {
                "keywords": [
                    "机构调研",
                    "涨幅翻倍"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "超千家机构调研这家公司，多只机构调研股涨幅翻倍",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-08",
            "original_text": "机构扎堆调研造就另类牛股",
            "features": {
                "keywords": [
                    "机构扎堆",
                    "调研",
                    "牛股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "机构扎堆调研造就另类牛股",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-10-09",
            "original_text": "机构扎堆调研造就另类牛股 多只“扎堆股”股价翻倍",
            "features": {
                "keywords": [
                    "机构扎堆",
                    "调研",
                    "牛股",
                    "股价翻倍"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "机构扎堆调研造就另类牛股 多只“扎堆股”股价翻倍",
                "Correlation": 6,
                "Sentiment": 9,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-10",
            "original_text": "靠副业日赚 1 亿！医疗大佬转做地产，建最顶级豪宅，秒杀汤臣一品",
            "features": {
                "keywords": [
                    "副业",
                    "医疗大佬",
                    "地产",
                    "顶级豪宅",
                    "汤臣一品"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "地产",
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "靠副业日赚 1 亿！医疗大佬转做地产，建最顶级豪宅，秒杀汤臣一品",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 10,
                "Source_Recency": 7
            }
        }
    ]
]